Trial Profile
A Randomised, Double-blind, Parallel Group Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a Single Dose of GSK2269557 Administered Via the ELLIPTA™ Dry Powder Inhaler to Healthy Participants
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Jun 2023
Price :
$35
*
At a glance
- Drugs Nemiralisib (Primary)
- Indications Asthma; Bronchiectasis; Chronic obstructive pulmonary disease; Immunodeficiency disorders
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 07 May 2019 Results published in the Clinical Therapeutics
- 04 Aug 2017 Status changed from not yet recruiting to completed.
- 20 Jun 2017 New trial record